Back to search

Article

Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma

2025-11-12

Abstract excerpt

Temozolomide (TMZ) is the standard treatment for nearly all glioblastoma (GBM) patients, as it is the only chemotherapy shown to extend overall survival. However, this benefit is limited to a few months, underscoring the need for combination strategies to improve its efficacy. While TMZ-induced DNA damage can both mediate cytotoxicity and promote resistance, DNA damage more broadly can also stimulate immune activa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
93f68f83-1271-5193-86b2-a0b007545eac
DOI
10.1101/2025.11.10.687735
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastomaDOI 10.1101/2025.11.10.687735
Select a neighboring publication to make it the new centre.